351 related articles for article (PubMed ID: 25426699)
21. The role of B. pertussis vaccine antigen gene variants in pertussis resurgence and possible consequences for vaccine development.
Preston A
Hum Vaccin Immunother; 2016 May; 12(5):1274-6. PubMed ID: 26889694
[TBL] [Abstract][Full Text] [Related]
22. Whole-cell but not acellular pertussis vaccines induce convulsive activity in mice: evidence of a role for toxin-induced interleukin-1beta in a new murine model for analysis of neuronal side effects of vaccination.
Donnelly S; Loscher CE; Lynch MA; Mills KH
Infect Immun; 2001 Jul; 69(7):4217-23. PubMed ID: 11401957
[TBL] [Abstract][Full Text] [Related]
23. Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model.
Denoël P; Godfroid F; Guiso N; Hallander H; Poolman J
Vaccine; 2005 Nov; 23(46-47):5333-41. PubMed ID: 16054273
[TBL] [Abstract][Full Text] [Related]
24. Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis.
Vandebriel RJ; Gremmer ER; Vermeulen JP; Hellwig SM; Dormans JA; Roholl PJ; Mooi FR
Vaccine; 2007 Mar; 25(12):2346-60. PubMed ID: 17224216
[TBL] [Abstract][Full Text] [Related]
25. Pertussis of adults and infants.
von König CH; Halperin S; Riffelmann M; Guiso N
Lancet Infect Dis; 2002 Dec; 2(12):744-50. PubMed ID: 12467690
[TBL] [Abstract][Full Text] [Related]
26. Possible options for new pertussis vaccines.
Meade BD; Plotkin SA; Locht C
J Infect Dis; 2014 Apr; 209 Suppl 1():S24-7. PubMed ID: 24626868
[TBL] [Abstract][Full Text] [Related]
27. Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.
Dorji D; Mooi F; Yantorno O; Deora R; Graham RM; Mukkur TK
Med Microbiol Immunol; 2018 Feb; 207(1):3-26. PubMed ID: 29164393
[TBL] [Abstract][Full Text] [Related]
28. Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines.
Esposito S; Stefanelli P; Fry NK; Fedele G; He Q; Paterson P; Tan T; Knuf M; Rodrigo C; Weil Olivier C; Flanagan KL; Hung I; Lutsar I; Edwards K; O'Ryan M; Principi N;
Front Immunol; 2019; 10():1344. PubMed ID: 31333640
[TBL] [Abstract][Full Text] [Related]
29. Waning vaccine immunity in teenagers primed with whole cell and acellular pertussis vaccine: recent epidemiology.
Sheridan SL; Frith K; Snelling TL; Grimwood K; McIntyre PB; Lambert SB
Expert Rev Vaccines; 2014 Sep; 13(9):1081-106. PubMed ID: 25093268
[TBL] [Abstract][Full Text] [Related]
30. National study of infants hospitalized with pertussis in the acellular vaccine era.
Elliott E; McIntyre P; Ridley G; Morris A; Massie J; McEniery J; Knight G
Pediatr Infect Dis J; 2004 Mar; 23(3):246-52. PubMed ID: 15014301
[TBL] [Abstract][Full Text] [Related]
31. Reduced risk of pertussis in whole-cell compared to acellular vaccine recipients is not confounded by age or receipt of booster-doses.
Sheridan SL; Ware RS; Grimwood K; Lambert SB
Vaccine; 2015 Sep; 33(39):5027-30. PubMed ID: 26297874
[TBL] [Abstract][Full Text] [Related]
32. Whooping cough, twenty years from acellular vaccines introduction.
Greco D; Esposito S; Tozzi A; Pandolfi E; Icardi G; Giammanco A
Ann Ig; 2015; 27(2):415-31. PubMed ID: 26051141
[TBL] [Abstract][Full Text] [Related]
33. Acellular pertussis vaccines in China.
Wang L; Lei D; Zhang S
Vaccine; 2012 Nov; 30(50):7174-8. PubMed ID: 23084855
[TBL] [Abstract][Full Text] [Related]
34. The control of pertussis--2007 and beyond.
Halperin SA
N Engl J Med; 2007 Jan; 356(2):110-3. PubMed ID: 17215528
[No Abstract] [Full Text] [Related]
35. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
[TBL] [Abstract][Full Text] [Related]
36. Pertussis vaccine trials in the 1990s.
Lambert LC
J Infect Dis; 2014 Apr; 209 Suppl 1(Suppl 1):S4-9. PubMed ID: 24626871
[TBL] [Abstract][Full Text] [Related]
37. Different T cell memory in preadolescents after whole-cell or acellular pertussis vaccination.
Smits K; Pottier G; Smet J; Dirix V; Vermeulen F; De Schutter I; Carollo M; Locht C; Ausiello CM; Mascart F
Vaccine; 2013 Dec; 32(1):111-8. PubMed ID: 24176499
[TBL] [Abstract][Full Text] [Related]
38. What to do about pertussis vaccines? Linking what we know about pertussis vaccine effectiveness, immunology and disease transmission to create a better vaccine.
Bolotin S; Harvill ET; Crowcroft NS
Pathog Dis; 2015 Nov; 73(8):ftv057. PubMed ID: 26253079
[TBL] [Abstract][Full Text] [Related]
39. Proteomics of Bordetella pertussis whole-cell and acellular vaccines.
Möller J; Kraner ME; Burkovski A
BMC Res Notes; 2019 Jun; 12(1):329. PubMed ID: 31182148
[TBL] [Abstract][Full Text] [Related]
40. Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults--a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience.
Thierry-Carstensen B; Dalby T; Stevner MA; Robbins JB; Schneerson R; Trollfors B
Vaccine; 2013 Oct; 31(45):5178-91. PubMed ID: 23994021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
